可溶型メソテリン関連蛋白(SMRP: Soluble Mesothelin-related Peptides)の悪性胸膜中皮腫におけるバイオマーカーとしての意義

Soluble Mesothelin-related Peptides (SMRP) as a Biomarker for Malignant Pleural Mesothelioma

Hirashima Tomonori

Fukuoka Kazuya

Hida Toyoaki

Kawahara Kunimitsu

Kishimoto Takumi

Matsumura Akihide

Nakano Kikuo

Okada Morihito

Nakano Takashi

肺癌

悪性胸膜中皮腫はアスベスト曝露に起因する難治性悪性腫瘍であり,我が国においては2030年まで増加し続けることが予測されている.これまで,悪性胸膜中皮腫のバイオマーカーについての検討は少なく,補助診断あるいは治療効果や予後予測に際して有用かつ信頼できるバイオマーカーはなかった.今回,我々は,悪性胸膜中皮腫診断における可溶型メソテリン関連蛋白(SMRP: soluble mesothelin-related peptides)のバイオマーカーとしての意義を前向きの多施設共同研究で検討した.本稿では,悪性胸膜中皮腫に関する知見,治療法,および診断のためのバイオマーカーについて特に重要な論文を中心にレビューし,さらに,我々が行った前向きの多施設共同研究の結果の一部を報告する.

Malignant pleural mesothelioma (MPM) is a highly aggressive, incurable neoplasm associated with asbestos exposure. It is estimated that the incidence of this disease will continue to increase until at least the year 2030 in Japan. There is some evidence that patients with MPM respond better to treatment if it is delivered early in the disease. A few MPM biomarkers have been reported, but until recently, no reliable serum marker to help the diagnosis of MPM or to predict response to treatment or prognosis, had been identified. Therefore, we performed a prospective, multicenter study to evaluate the significance of soluble mesothelin-related peptides (SMRP) as a biomarker for diagnosis of MPM. In this paper, we review the key advances in the understanding, treatment, and a biomarker for the diagnosis of MPM. Furthermore, we report some results of a prospective, multicenter study.

悪性胸膜中皮腫

メソテリン

SMRP

バイオマーカー

Malignant pleural mesothelioma

Mesothelin

Soluble mesothelin-related peptides

Biomarker

Medical sciences [ 490 ]

jpn

日本肺癌学会

Copyright (c) 2009 日本肺癌学会

[ISSN] 0386-9628

[NCID] AN00203978

[DOI] 10.2482/haigan.49.380

[URI] http://joi.jlc.jst.go.jp/JST.JSTAGE/haigan/49.380 isVersionOf